<DOC>
	<DOCNO>NCT00239629</DOCNO>
	<brief_summary>The aim study directly compare bone forming effect 20 microg/day teriparatide 2 g/day strontium ranelate measure histomorphometric variable biochemical bone formation marker 6 month therapy postmenopausal woman osteoporosis .</brief_summary>
	<brief_title>Teriparatide Strontium Ranelate Head-To-Head Comparison Trial</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis , Postmenopausal</mesh_term>
	<mesh_term>Strontium ranelate</mesh_term>
	<mesh_term>Teriparatide</mesh_term>
	<criteria>INCLUSION CRITERIA : 1 . Ambulatory , postmenopausal woman age 45 90 year inclusive time entry trial , whose last menstrual period bilateral oophorectomy occur least 5 year prior entry trial . Women age 55 year bilateral oophorectomy clearly document must postmenopausal status confirm serum FSH level great equal 30 IU/L serum estradiol level lower equal 20 pg/ml low equal 73 pmol/L . 2 . Free severe chronically disable condition osteoporosis . 3 . Able use pentype injection delivery system satisfactorily opinion investigator willing train use peninjector daily basis . 4 . Without language barrier , cooperative , expect return followup procedure , give informed consent inform risk , medication , procedure use study . 5 . Posterioranterior lumbar spine ( L1 L4 ) BMD and/or femoral neck BMD and/or total hip BMD measurement least 2.5 standard deviation ( SD ) average bone mass young woman ( Tscore equal 2.5 standard deviation ) . The lumbar spine hip BMD assessment determination patient 's eligibility entry screen phase make individual investigator . Any lumbar vertebra analyze due artifact , severe crush fracture , osteophytes , abnormality , exclude analysis . A minimum two lumbar vertebra L1 L4 region must evaluable DXA anatomical site BMD cutoff level le 2.5 SD demonstrate . A DXA assessment perform within three month prior Visit 1 may acceptable patient 's eligibility . 6 . Normal clinically insignificant abnormal laboratory value ( define investigator ) include serum calcium , PTH ( 1 84 ) , alkaline phosphatase . EXCLUSION CRITERIA : 7 . History unresolved skeletal disease affect bone metabolism postmenopausal osteoporosis include Paget 's disease , renal osteodystrophy , osteomalacia , secondary cause osteoporosis , hyperparathyroidism ( uncorrected ) , intestinal malabsorption . 8 . In opinion investigator , medical anatomical condition potentially could put patient additional risk adverse event due biopsy procedure ( example , coagulation abnormality , anticoagulant medication , extreme obesity , etc ) . 9 . Have undergone two previous iliac bone biopsy ( one iliac crest ) . Patients one previous iliac bone biopsy eligible provide new sample obtain contralateral iliac crest . 10 . History malignant neoplasms 5 year prior Visit 1 , exception superficial basal cell carcinoma squamous cell carcinoma skin definitively treat . Patients carcinoma situ uterine cervix treat definitively 1 year prior entry study may randomize . 11 . Increased baseline risk osteosarcoma ; include subject Paget 's disease bone , previous primary skeletal malignancy , skeletal exposure therapeutic irradiation , i.e . prior external beam implant radiation therapy . As elevation serum skeletal alkaline phosphatase activity may indicate presence Paget 's disease , unexplained elevation enzyme activity also exclusionary . 12 . Abnormal thyroid function correct therapy . Normal thyroid function may document normal TSH screen phase combination clinical biochemical parameter , judgment investigator Lilly Clinical Research Physician , sufficiently establish presence normal thyroid function . 13 . Active liver disease clinical jaundice . 14 . Significantly impaired renal function define either follow criterion : Serum creatinine , opinion investigator , indicate significant renal impairment . Measured calculate endogenous creatinine clearance le 30 mL/min use follow Cockcroft Gault formula creatinine clearance ( ClCr ) woman : ClCr ( mL/minute ) = [ [ ( 140age ) x weight ( kg ) ] x0.85 ] / [ 72 x serum Cr ( mg/dL ) ] 15 . Current past treatment bisphosphonate , parathyroid hormone analog , androgens anabolic steroid therapeutic dos fluorides time prior Visit 2 . Past treatment ( 12 month Visit 2 ) selective estrogen receptor modulator ( SERM ) , nasal injectable calcitonin , oral , transdermal , injectable estrogen , progestin , estrogen analog , estrogen agonist , estrogen antagonist tibolone allow . Previous current use fluoridate water topical dental fluoride treatment permit . 16 . Treatment Vitamin D great 50,000 IU/week , dose calcitriol Vitamin D analog agonists 6 month prior Visit 2 . 17 . Treatment systemic corticosteroid last month prior Visit 2 14 day 1 year prior Visit 2 . Ophthalmic , otic , topical , orally inhale , nasally inhale , intraarticular corticosteroid therapy may use without restriction . However , orally inhale nasally inhaled corticosteroid dos great 840 micrograms/day beclomethasone dipropionate equivalent 14 day last year prior randomization disqualifying .</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>June 2007</verification_date>
</DOC>